Company: RGNX
Filing Date: 2025-06-13
Form Type: S-3
Source: 0001193125-25-140870
Chunk: 19

Company: REGENXBIO Inc.
Filing Date: 2025-06-13
Form: S-3
Chunk 19
---
 prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.

The Selling Stockholder may authorize agents, dealers or underwriters to solicit certain institutional investors to purchase Shares on a
delayed delivery basis pursuant to delayed delivery contracts providing for payment and delivery on a specified future date.

The Selling
Stockholder will enter into such delayed contracts only with institutional purchasers that it approves. These institutions may include commercial and savings banks, insurance companies, pension funds, investment companies and educational and
charitable institutions.

In order to comply with the securities laws of some states, if applicable, the Shares may be sold in these
jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the Shares may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is
available and is complied with.

The Selling Stockholder may have agreements with agents, underwriters, dealers and remarketing firms to
indemnify them against certain civil liabilities, including liabilities under the Securities Act. Agents, underwriters, dealers and remarketing firms, and their affiliates, may engage in transactions with, or perform services for, the Selling
Stockholder in the ordinary course of business. This includes commercial banking and investment banking transactions.

The Selling
Stockholder and any other person participating in a sale of the Shares registered under this prospectus will be subject to applicable provisions of the Exchange Act, and the rules and regulations thereunder, including, without limitation, to the
extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the Shares by the Selling Stockholder and any other participating person. All of the foregoing may affect the marketability of the
Shares and the ability of any person or entity to engage in market-making activities with respect to the Shares. In addition, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the Selling
Stockholder for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Selling Stockholder may indemnify any broker-dealer that participates in transactions involving the sale of the Shares against certain
liabilities, including liabilities arising under the Securities Act.

13

In connection with any offering of Shares, the underwriters may purchase and sell shares of
our common stock in the open market. These transactions may include short sales, syndicate covering transactions and stabilizing transactions. Short sales involve syndicate sales